A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Protein tyrosine kinases (PTKs) regulate cellular functions, but their deregulation, as seen with Bcr-Abl in chronic myeloid leukemia (CML), drives cancer.
• The success of imatinib in CML highlights PTKs as crucial targets for novel cancer therapeutics.

Purpose of the Study:

• To develop and validate a novel, sensitive, and reproducible assay for measuring PTK activity.
• To enable efficient small molecule screening for PTK inhibitors.

Main Methods:

• A hydrogel-based platform immobilizing peptide substrates via acrylate crosslinkers and thiol-presenting surfaces.
• Detection of peptide phosphorylation using anti-phosphotyrosine antibodies and chemifluorescence.
• Assay validation with recombinant c-Abl, Bcr-Abl in cell extracts, and known PTK inhibitors.

Main Results:

• The hydrogel assay demonstrated low background and high reproducibility for semiquantitative detection of PTK phosphorylation.
• The method successfully measured c-Abl and Bcr-Abl activity in cell lysates.
• Model screens identified inhibition by commercial PTK inhibitors and pyridopyrimidine Src/Abl dual inhibitors.

Conclusions:

• This hydrogel-immobilized peptide assay is a practical and sensitive tool for measuring kinase activity in complex biological samples.
• The assay is valuable for high-throughput screening of small molecules targeting PTKs for cancer drug discovery.